<?xml version="1.0" encoding="UTF-8"?>
<ref id="B21-antibiotics-09-00909">
 <label>21.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Vila</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Hebert</surname>
    <given-names>A.A.</given-names>
   </name>
   <name>
    <surname>Torrelo</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Lopez</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Tato</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Garcia-Castillo</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Canton</surname>
    <given-names>R.</given-names>
   </name>
  </person-group>
  <article-title>Ozenoxacin: A review of preclinical and clinical efficacy</article-title>
  <source>Expert Rev. Anti Infect. Ther.</source>
  <year>2019</year>
  <volume>17</volume>
  <fpage>159</fpage>
  <lpage>168</lpage>
  <pub-id pub-id-type="doi">10.1080/14787210.2019.1573671</pub-id>
  <pub-id pub-id-type="pmid">30686133</pub-id>
 </element-citation>
</ref>
